Thursday 16 October, 2025
Objectives: Moxifloxacin, a fluoroquinolone antibiotic, is a priority drug for the treatment of rifampicin-resistant tuberculosis (RR-TB). The standard 400 mg tablet…
Read moreAbstracts
Translational modelling of tumor growth inhibition and treatment resistance for a molecule targeting apoptosis pathway
Thursday 16 October, 2025
Objectives: A small molecule (drug S) is currently under development for treatment of cancer patients, targeting the regulation of apoptosis….
Read moreRituximab in Anti‑Neutrophil Cytoplasmic Antibodies (ANCA)-associated vasculitis: population pharmacokinetic modeling and simulations of alternative doses in under-exposed patients
Thursday 16 October, 2025
Objectives: Rituximab is a monoclonal antibody directed against transmembrane antigen CD20 expressed by B cells. It is approved for the…
Read morePharmpy: a versatile open-source library for pharmacometrics
Thursday 16 October, 2025
The development of pharmacometric nonlinear mixed effect models is a complex, multi-step process. Generally, it begins with an informed starting…
Read morePopulation pharmacokinetics of moxifloxacin in Indian patients with multi-drug resistance tuberculosis
Thursday 16 October, 2025
Introduction: Moxifloxacin (MFX) is an 8-methoxy quinolone metabolized in the liver through sulfate and glucuronide conjugation by uridine diphosphate- glucuronosyltransferases…
Read moreWhat is the effective concentration of dolutegravir? A pharmacokinetic/pharmacodynamic analysis.
Thursday 16 October, 2025
Introduction: The minimum effective concentration (MEC) of dolutegravir (DTG) is not well defined. Putative trough concentration (Ctrough) targets have been…
Read moreA pragmatic approach to handling data below the lower limit of quantification in complex pharmacokinetic models
Thursday 16 October, 2025
Objectives: Adequate handling of data below the lower limit of quantification (BLQ) is key for parameter estimation in population pharmacokinetic (PK)…
Read moreEthambutol population pharmacokinetics in South African patients with drug-susceptible tuberculosis
Thursday 16 October, 2025
Objectives: Ethambutol is one of four drugs given during the initial two-month intensive phase of drug-susceptible tuberculosis treatment. Ethambutol is…
Read moreAnalysis of Mycobacterium tuberculosis time to positivity in response to treatment in South African patients with drug-susceptible tuberculosis
Thursday 16 October, 2025
Objectives: Tuberculosis is the leading cause of death from an infectious agent worldwide[1]. Tuberculosis burden is high in South Africa,…
Read moreJoint modeling of biomarkers dynamics and survival with competing risks to predict the prognostic of patients hospitalized with severe infectious diseases
Thursday 16 October, 2025
Objectives: Nowadays, most hospitals are equipped with laboratory information systems that routinely gather all results of biological analyses prescribed by the…
Read more